Distinguishing follicular carcinoma from follicular adenoma, based on cytomorphological
features, has always been challenging to cytopathologists. Identification of biomarkers for
improving diagnostic accuracy is important for clinical management. Meanwhile, it is critical
to identify therapeutic target candidates for treatment of follicular carcinoma. Currently, no
reliable diagnostic protein biomarkers and therapeutic targets are available. To explore
novel protein biomarker and therapeutic target candidates, a liquid chromatography-tandem …

Follicular adenoma is a type of benign and encapsulated nodule in the thyroid gland, but
some adenomas have the potential to progress to follicular carcinoma. Therefore, it is
important to monitor the state and progress of follicular adenoma in the clinic and discover
drug development targets for the treatment of follicular adenoma to prevent its worsening to
follicular carcinoma. Currently, the study of biomarkers and therapeutic targets lacks
applications of up-to-date technologies, including proteomics and bioinformatics. To …